Stockreport

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF Once issued, this patent provides U.S. intellectual property coverage of UroGen’s RTGel® technology with medac lyophilized mitomycin formulation, covering UGN-103 and UG [Read more]